Get the Stockscreener App
15.73
2.36%
-0.38
After Hours:
15.73
Nurix Therapeutics Inc stock is traded at $15.73, with a volume of 546.19K.
It is down -2.36% in the last 24 hours and down -14.42% over the past month.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
See More
Previous Close:
$16.11
Open:
$16.31
24h Volume:
546.19K
Relative Volume:
0.37
Market Cap:
$1.62B
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-5.4429
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-1.38%
1M Performance:
-14.42%
6M Performance:
+56.99%
1Y Performance:
-9.13%
1-Day Range:
$15.33
$16.37
1-Week Range:
$15.33
$17.03
52-Week Range:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
15.73 | 1.66B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
Stifel raised Nurix Therapeutics, Inc. (NRIX) price target to $35 and maintains buy ahead of 2026 catalysts - MSN
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Is Nurix Therapeutics Inc forming a bullish divergenceWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Finviz
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Finviz
Research Analysts Offer Predictions for NRIX Q1 Earnings - MarketBeat
Published on: 2026-02-01 10:49:34 - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - 富途牛牛
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking A 70% Upside Potential - DirectorsTalk Interviews
Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure - The Globe and Mail
Nurix Therapeutics chief legal officer Ring sells $73k in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics chief legal officer Ring sells $73k in stock - Investing.com UK
Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,895 Shares - MarketBeat
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Finviz
Nurix Therapeutics CSO Gwenn Hansen sells $81k in shares By Investing.com - Investing.com Canada
Nurix Therapeutics CFO Hans van Houte sells $61k in shares - Investing.com Canada
Big Picture: Can Artius II Acquisition Inc Equity Right be the next market leaderWeekly Stock Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Should I buy Nurix Therapeutics Inc stock now2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - Sahm
Stock Analysis: Will Nurix Therapeutics Inc be affected by tariffsQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Momentum Shift: Can THTX expand into new marketsMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
HC Wainwright Raises Price Target for NRIX, Reaffirms Buy Rating - GuruFocus
Nurix Therapeutics price target raised to $35 from $33 at Stifel - TipRanks
Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t - GuruFocus
Royal Bank Of Canada Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
NRIX: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus
NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating - GuruFocus
NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig - GuruFocus
NRIX Analyst Jeet Mukherjee Reiterates Buy Rating, Target Stays at $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Earns "Buy" Rating from BTIG Research - MarketBeat
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo - TipRanks
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler - TipRanks
NRIX: Needham Reiterates Buy Rating with Stable Price Target | N - GuruFocus
What 11 Analyst Ratings Have To Say About Nurix Therapeutics - Benzinga
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
A Look At Nurix Therapeutics (NRIX) Valuation As DAYBreak Phase 2 Trial Progresses - Sahm
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Nurix (NRIX) Achieves Key Milestone with Q4 Revenue and Program Launch - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 6.7%Time to Sell? - MarketBeat
Nurix Therapeutics Announces Initiation of DAYBreak™ Program for Bexobrutideg in Relapsed/Refractory CLL with Promising Phase 1 Results - Quiver Quantitative
Nurix Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q4 Revenue $13.6M, vs. FactSet Est of $13.4M - marketscreener.com
NRIX: Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves - TradingView
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):